Ikena Oncology, Inc. (IKNA)
NASDAQ: IKNA · Real-Time Price · USD
1.320
-0.010 (-0.75%)
At close: Mar 28, 2025, 4:00 PM
1.350
+0.030 (2.25%)
After-hours: Mar 28, 2025, 5:59 PM EDT
Ikena Oncology Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Ikena Oncology stock have an average target of 3.00, with a low estimate of 2.00 and a high estimate of 4.00. The average target predicts an increase of 127.27% from the current stock price of 1.32.
Analyst Consensus: Buy
* Price targets were last updated on Nov 11, 2024.
Analyst Ratings
The average analyst rating for Ikena Oncology stock from 2 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +203.03% | Nov 11, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +203.03% | Aug 12, 2024 |
| Wedbush | Wedbush | Buy → Hold Downgrades $8 → $2 | Buy → Hold | Downgrades | $8 → $2 | +51.52% | May 29, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $11 → $4 | Strong Buy | Maintains | $11 → $4 | +203.03% | May 29, 2024 |
| Wedbush | Wedbush | Buy Reiterates $8 | Buy | Reiterates | $8 | +506.06% | May 14, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.84
from -1.02
EPS Next Year
-0.93
from -0.84
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | ||
| Avg | n/a | n/a | n/a | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.71 | -0.65 | -0.58 |
| Avg | -0.84 | -0.93 | -0.56 |
| Low | -0.96 | -1.14 | -0.54 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.